X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (19) 19
humans (17) 17
male (17) 17
prostate cancer (16) 16
article (13) 13
oncology (13) 13
aged (12) 12
middle aged (11) 11
treatment outcome (10) 10
cancer (9) 9
aged, 80 and over (8) 8
chemotherapy (8) 8
medicine & public health (7) 7
metastasis (7) 7
pharmacology & pharmacy (7) 7
prostatic neoplasms, castration-resistant - drug therapy (7) 7
pharmacology/toxicology (6) 6
prostatic neoplasms, castration-resistant - pathology (6) 6
care and treatment (5) 5
clinical-trials (5) 5
docetaxel (5) 5
prostatic neoplasms - pathology (5) 5
tumors (5) 5
adult (4) 4
antineoplastic agents - therapeutic use (4) 4
antineoplastic combined chemotherapy protocols - administration & dosage (4) 4
antineoplastic combined chemotherapy protocols - adverse effects (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
clinical trials (4) 4
disease progression (4) 4
dose-response relationship, drug (4) 4
drug therapy (4) 4
end-points (4) 4
increased survival (4) 4
pharmacology (4) 4
prednisone (4) 4
prostate-specific antigen - blood (4) 4
prostatic neoplasms - drug therapy (4) 4
recommendations (4) 4
research (4) 4
studies (4) 4
analysis (3) 3
antineoplastic agents - administration & dosage (3) 3
antineoplastic agents - adverse effects (3) 3
antineoplastic agents - pharmacokinetics (3) 3
antitumor activity (3) 3
apoptosis (3) 3
bone neoplasms - secondary (3) 3
cancer research (3) 3
castration (3) 3
cells (3) 3
disease-free survival (3) 3
drug administration schedule (3) 3
enzalutamide (3) 3
fatigue (3) 3
female (3) 3
genetic aspects (3) 3
histone deacetylase inhibitors (3) 3
hydroxamic acids - administration & dosage (3) 3
hydroxamic acids - adverse effects (3) 3
inhibitor (3) 3
maximum tolerated dose (3) 3
medical research (3) 3
mitoxantrone (3) 3
neoplasm metastasis (3) 3
neoplasms - drug therapy (3) 3
orchiectomy (3) 3
paclitaxel (3) 3
prostate (3) 3
suberoylanilide hydroxamic acid (3) 3
taxoids - administration & dosage (3) 3
urology (3) 3
vorinostat (3) 3
abiraterone (2) 2
abiraterone acetate (2) 2
abridged index medicus (2) 2
anticancer properties (2) 2
antigen (2) 2
antimitotic agents (2) 2
antineoplastic agents (2) 2
antineoplastic agents, hormonal - therapeutic use (2) 2
antineoplastic combined chemotherapy protocols - pharmacokinetics (2) 2
biochemistry & molecular biology (2) 2
biochemistry, genetics and molecular biology (2) 2
bladder cancer (2) 2
bone neoplasms - radiotherapy (2) 2
cancer patients (2) 2
carcinoma (2) 2
castration-resistant (2) 2
castration-resistant prostate cancer (2) 2
cdks and cdk inhibitors (2) 2
cell biology (2) 2
cellular signal transduction (2) 2
circulating tumor-cells (2) 2
cohort studies (2) 2
combination chemotherapy (2) 2
corticosteroids (2) 2
diarrhea (2) 2
dosage and administration (2) 2
double-blind method (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2010, Volume 375, Issue 9724, pp. 1437 - 1446
Journal Article
Lancet Oncology, ISSN 1470-2045, 2013, Volume 14, Issue 12, pp. 1193 - 1199
Journal Article
Lancet Oncology, ISSN 1470-2045, 2015, Volume 16, Issue 2, pp. 152 - 160
Journal Article
by Robinson, Brian D and Robinson, Dan and Van Allen, Eliezer M and Wu, Yi-Mi and Schultz, Nikolaus and Lonigro, Robert J and Mosquera, Juan-Miguel and Montgomery, Bruce and Taplin, Mary-Ellen and Pritchard, Colin C and Attard, Gerhardt and Beltran, Himisha and Abida, Wassim and Bradley, Robert K and Vinson, Jake and Cao, Xuhong and Vats, Pankaj and Kunju, Lakshmi P and Hussain, Maha and Feng, Felix Y and Tomlins, Scott A and Cooney, Kathleen A and Smith, David C and Brennan, Christine and Siddiqui, Javed and Mehra, Rohit and Chen, Yu and Rathkopf, Dana E and Morris, Michael J and Solomon, Stephen B and Durack, Jeremy C and Reuter, Victor E and Gopalan, Anuradha and Gao, Jianjiong and Loda, Massimo and Lis, Rosina T and Bowden, Michaela and Balk, Stephen P and Gaviola, Glenn and Sougnez, Carrie and Gupta, Manaswi and Yu, Evan Y and Mostaghel, Elahe A and Cheng, Heather H and Mulcahy, Hyojeong and True, Lawrence D and Plymate, Stephen R and Dvinge, Heidi and Ferraldeschi, Roberta and Flohr, Penny and Miranda, Susana and Zafeiriou, Zafeiris and Tunariu, Nina and Mateo, Joaquin and Perez-Lopez, Raquel and Demichelis, Francesca and Schiffman, Marc and Nanus, David M and Tagawa, Scott T and Sigaras, Alexandros and Eng, Kenneth W and Elemento, Olivier and Sboner, Andrea and Heath, Elisabeth I and Scher, Howard I and Pienta, Kenneth J and Kantoff, Philip and de Bono, Johann S and Rubin, Mark A and Nelson, Peter S and Garraway, Levi A and Sawyers, Charles L and Chinnaiyan, Arul M
Cell, ISSN 0092-8674, 05/2015, Volume 161, Issue 5, pp. 1215 - 1228
Journal Article
Cell, ISSN 0092-8674, 09/2014, Volume 159, Issue 1, pp. 176 - 187
Journal Article
Investigational New Drugs, ISSN 0167-6997, 6/2018, Volume 36, Issue 3, pp. 458 - 467
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 9/2013, Volume 72, Issue 3, pp. 537 - 544
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 5/2010, Volume 66, Issue 1, pp. 181 - 189
Histone deacetylase inhibitors have demonstrated anticancer activity against a range of tumors. We aimed to define the maximum tolerated dose, toxicity,... 
Panobinostat | Histone deacetylase inhibitor | Medicine & Public Health | Docetaxel | Oncology | Cancer Research | Castration-resistant | Pharmacology/Toxicology | Prostate cancer | ANDROGEN RECEPTOR | SUBEROYLANILIDE HYDROXAMIC ACID | REPRODUCIBILITY | CIRCULATING TUMOR-CELLS | ONCOLOGY | RECOMMENDATIONS | CLINICAL-TRIALS | END-POINTS | MALIGNANCIES | PHARMACOLOGY & PHARMACY | PET | Humans | Hydroxamic Acids - adverse effects | Middle Aged | Histone Deacetylase Inhibitors - administration & dosage | Drug Resistance, Neoplasm | Male | Positron-Emission Tomography | Histone Deacetylase Inhibitors - pharmacokinetics | Neoplasm Metastasis | Aged, 80 and over | Hydroxamic Acids - administration & dosage | Prostate-Specific Antigen - drug effects | Prostatic Neoplasms - diagnostic imaging | Indoles | Prostatic Neoplasms - drug therapy | Prostatic Neoplasms - pathology | Neoplastic Cells, Circulating - drug effects | Administration, Oral | Treatment Outcome | Prostate-Specific Antigen - blood | Histones - blood | Hydroxamic Acids - pharmacokinetics | Taxoids - administration & dosage | Acetylation - drug effects | Maximum Tolerated Dose | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Fluorodeoxyglucose F18 | Aged | Histone Deacetylase Inhibitors - adverse effects | Medical colleges | Antigens | Care and treatment | Oncology, Experimental | Research | DNA binding proteins | Antineoplastic agents | Antimitotic agents | Cancer patients | Histones | Injuries | Tumors | Cancer | Index Medicus
Journal Article
ONCOLOGY (United States), ISSN 0890-9091, 08/2014, Volume 28, Issue 8
Journal Article
Journal Article
Journal Article